U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155278) titled 'Efficacy & Safety of hADM Skin Booster' on Aug. 26.
Brief Summary: The goal of this randomized, split-face, double-blinded clinical trial is to evaluate the efficacy and safety of Elravie Re2O (particulated human Acellular Dermal Matrix, phADM) as a skin booster compared with hyaluronic acid (HA) skin booster alone in adults with skin roughness.
The main questions it aims to answer are:
1. Does phADM combined with HA improve objective skin measurements and subjective skin assessments more effectively than HA alone?
2. Is phADM + HA treatment safe and well tolerated?
Researchers will compare one half of participant's face treated...